Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828125 | 0.89 | TSHR (0.44) | TSHRHTTLMNAKDM4ENPC1 | |
| SCHEMBL13845817 | 0.82 | HTT (0.52) | TSHRHTTLMNAKDM4ENPC1 | |
| SCHEMBL5128474 | 0.80 | TSHR (0.44) | TSHRHTTLMNAKDM4ENPC1 | |
| SCHEMBL14306234 | 0.78 | TSHR (0.57) | TSHRHTTLMNAKDM4ENCF1 | |
| SCHEMBL4830082 | 0.77 | TSHR (0.44) | TSHRHTTLMNAKDM4EACP1 | |
| SCHEMBL4830050 | 0.73 | TSHR (0.41) | TSHRHTTLMNAKDM4ENPC1 | |
| SCHEMBL4631944 | 0.73 | TSHR (0.61) | TSHRHTTLMNAKDM4ENPC1 | |
| SCHEMBL14320172 | 0.73 | UTS2R (0.44) | TSHRHTTLMNAKDM4EACP1 | |
| SCHEMBL13845816 | 0.72 | L3MBTL1 (0.54) | TSHRHTTLMNAKDM4ENPC1 | |
| SCHEMBL4632728 | 0.72 | TSHR (0.59) | TSHRHTTLMNAKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | TSHR 1103/4885HTT 1829/4885LMNA 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.